Skip to content

Zymeworks ZYME Income taxes at U.S. statutory rate of 21%

Income taxes at U.S. statutory rate of 21% at other companies

AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
27%0.0pp
Charles River Laboratories logo
Charles River LaboratoriesCRL
21%0.0pp
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
21%0.0pp

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's income taxes at u.s. statutory rate of 21%.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's income taxes at U.S. statutory rate of 21%?
Zymeworks (ZYME) reported income taxes at U.S. statutory rate of 21% of 21% in Q4 2025.
What does income taxes at U.S. statutory rate of 21% mean?
Represents the income tax impact calculated specifically at the U.S. federal statutory rate, typically 21%, applied to the company's earnings before taxes. This is a standard benchmark used to isolate the impact of various tax adjustments and credits on the overall tax burden.